AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Biliary Tract Cancer (ASCEND-BTC)
NCT ID: NCT05667350
Last Updated: 2022-12-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
492 participants
OBSERVATIONAL
2022-02-28
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cancer arm
Baseline blood samples will be collected from participants newly diagnosed with biliary tract cancer.
Blood drawing
Blood drawing before anti-cancer therapy
Benign disease arm
Baseline blood samples will be collected from participants newly diagnosed with benign biliary tract diseases.
Blood drawing
Blood drawing before radical treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood drawing
Blood drawing before anti-cancer therapy
Blood drawing
Blood drawing before radical treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to provide a written informed consent
* Pathologically confirmed biliary tract cancers.
* No prior or ongoing anti-cancer therapy (local or systematic) prior to study blood draw.
* Age 40-75 years at the day of consenting to the study.
* Able to provide a written informed consent.
* Confirmed diagnosis of benign biliary tract diseases.
* No prior radical treatment of the benign diseases prior to study blood draw.
Exclusion Criteria
* Recipients of organ transplant or prior non-autologous (allogeneic) bone marrow transplant or stem cell transplant.
* Recipients of blood transfusion within 7 days prior to study blood draw.
* Recipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancers.
* With other known malignant tumors or multiple primary tumors.
* Pregnancy or lactating women.
* Recipients of organ transplant or prior non-autologous (allogeneic) bone marrow transplant or stem cell transplant.
* Recipients of blood transfusion within 7 days prior to study blood draw.
* Recipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancers.
* Confirmed diagnosis of malignancies or precancerous lesion.
* A history of malignant tumors.
40 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangzhou Burning Rock Bioengineering Co., Ltd
UNKNOWN
Eastern Hepatobiliary Surgery Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiaoqing Jiang
Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiaoqing Jiang, MD/PhD
Role: PRINCIPAL_INVESTIGATOR
Eastern Hepatobiliary Surgery Hospital
Bin Li, MD/PhD
Role: PRINCIPAL_INVESTIGATOR
Eastern Hepatobiliary Surgery Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Eastern Hepatobiliary Surgery Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Leibo Xu, MD/PhD
Role: primary
Yuzi Zhang, MD/PhD
Role: backup
Bin Li, MD/PhD
Role: primary
Yuzi Zhang, MD/PhD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RSCD2021021
Identifier Type: -
Identifier Source: org_study_id